Toshiki Uchida

4.1k total citations
86 papers, 1.9k citations indexed

About

Toshiki Uchida is a scholar working on Pathology and Forensic Medicine, Genetics and Hematology. According to data from OpenAlex, Toshiki Uchida has authored 86 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 40 papers in Pathology and Forensic Medicine, 36 papers in Genetics and 31 papers in Hematology. Recurrent topics in Toshiki Uchida's work include Lymphoma Diagnosis and Treatment (36 papers), Chronic Lymphocytic Leukemia Research (28 papers) and Acute Myeloid Leukemia Research (14 papers). Toshiki Uchida is often cited by papers focused on Lymphoma Diagnosis and Treatment (36 papers), Chronic Lymphocytic Leukemia Research (28 papers) and Acute Myeloid Leukemia Research (14 papers). Toshiki Uchida collaborates with scholars based in Japan, United States and Greece. Toshiki Uchida's co-authors include Hidehiko Saito, Takashi Murate, Michinori Ogura, Tomomitsu Hotta, Kensei Tobinai, Tomohiro Kinoshita, Hirokazu Nagai, Kiyoshi Ando, Katsuro Tachibana and K. Ogawa and has published in prestigious journals such as Journal of Clinical Oncology, Blood and The Journal of the Acoustical Society of America.

In The Last Decade

Toshiki Uchida

81 papers receiving 1.9k citations

Peers

Countries citing papers authored by Toshiki Uchida

Since Specialization

Citations

This map shows the geographic impact of Toshiki Uchida's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Toshiki Uchida with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Toshiki Uchida more than expected).

Fields of papers citing papers by Toshiki Uchida

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Toshiki Uchida. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Toshiki Uchida. The network helps show where Toshiki Uchida may publish in the future.

Co-authorship network of co-authors of Toshiki Uchida

This figure shows the co-authorship network connecting the top 25 collaborators of Toshiki Uchida. A scholar is included among the top collaborators of Toshiki Uchida based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Toshiki Uchida. Toshiki Uchida is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Inotuzumab ozogamicin versus standard of care in Asian patients with relapsed/refractory acute lymphoblastic leukemia 2019 ·International Journal of Hematology ·Naohito Fujishima, Toshiki Uchida, Yasushi Onishi, Chul Won Jung, Yeow Tee Goh, Kiyoshi Ando, (unknown), Chiho Ono, (unknown), M. Luisa Paccagnella, Barbara Sleight, Erik Vandendries, Yosuke Fujii, Masayuki Hino	8
2	E7777 in Japanese patients with relapsed/refractory peripheral and cutaneous T‐cell lymphoma: A phase I study 2018 ·Cancer Science ·(unknown), Kiyoshi Ando, Michinori Ogura, Toshiki Uchida, Kensei Tobinai, Dai Maruyama, Masayuki Namiki, Tadashi Nakanishi	25
3	A phase I study of vorinostat combined with bortezomib in Japanese patients with relapsed or refractory multiple myeloma 2015 ·International Journal of Hematology ·Yoshiaki Ogawa, Michinori Ogura, Kensei Tobinai, Kiyoshi Ando, Tatsuya Suzuki, Takashi Watanabe, Ken Ohmachi, Toshiki Uchida, Mary E. Hanson, Yoshinobu Tanaka, Yasuhiro Koh, Takashi Shimamoto, Tomomitsu Hotta	11
4	Phase I Study of Clofarabine in Adult Patients with Acute Myeloid Leukemia in Japan 2013 ·Japanese Journal of Clinical Oncology ·T. Suzuki, Takahiro Yamauchi, (unknown), Tadashi Nagai, Kazuhiko Kakihana, Yoshinori Miyata, Toshiki Uchida, (unknown), (unknown)	3
5	A phase I/II study of ofatumumab (GSK1841157) in Japanese and Korean patients with relapsed or refractory B-cell chronic lymphocytic leukemia 2013 ·International Journal of Hematology ·Yoshiaki Ogawa, Michinori Ogura, Tatsuya Suzuki, Kiyoshi Ando, Toshiki Uchida, Yukari Shirasugi, Kensei Tobinai, Je‐Hwan Lee, (unknown), (unknown), Tomomitsu Hotta	10
6	Stable renal engraftment in a patient following successful tandem autologous/reduced-intensity conditioning allogeneic transplantation for treatment of multiple myeloma with del(17p) that developed as a post-transplantation lymphoproliferative disease following renal transplantation 2013 ·International Journal of Hematology ·Tomohiro Aoki, Masanobu Kasai, (unknown), (unknown), Takanobu Morishita, Tatsuya Suzuki, Makoto Tsujita, Norihiko Goto, Akio Katayama, Yoshihiko Watarai, Kazuharu Uchida, Masafumi Ito, (unknown), Toyonori Tsuzuki, Toshiki Uchida, Michinori Ogura	7
7	Phase I study of obinutuzumab (GA101) in Japanese patients with relapsed or refractory B‐cell non‐Hodgkin lymphoma 2012 ·Cancer Science ·Michinori Ogura, Kensei Tobinai, Kiyohiko Hatake, Toshiki Uchida, Tatsuya Suzuki, Yukio Kobayashi, Masakazu Mori, Yasuhito Terui, Masahiro Yokoyama, Tomomitsu Hotta	27
8	Phase I and II study of azacitidine in Japanese patients with myelodysplastic syndromes 2011 ·Cancer Science ·Toshiki Uchida, Yoshiaki Ogawa, Yukio Kobayashi, Takayuki Ishikawa, Haruhiko Ohashi, Tomoko Hata, Noriko Usui, Masafumi Taniwaki, Kazunori Ohnishi, Hideki Akiyama, Keiya Ozawa, Kazuma Ohyashiki, Shinichiro Okamoto, Akihiro Tomita, Shinji Nakao, Kensei Tobinai, Michinori Ogura, Kiyoshi Ando, Tomomitsu Hotta	33
9	Feasibility and pharmacokinetic study of bendamustine hydrochloride in combination with rituximab in relapsed or refractory aggressive B cell non‐Hodgkin’s lymphoma⁶ 2011 ·Cancer Science ·Michinori Ogura, Kiyoshi Ando, Masafumi Taniwaki, Takashi Watanabe, Toshiki Uchida, Ken Ohmachi, Yosuke Matsumoto, Kensei Tobinai, (unknown)	19
10	Phase I study of LY2469298, an Fc‐engineered humanized anti‐CD20 antibody, in patients with relapsed or refractory follicular lymphoma 2010 ·Cancer Science ·Kensei Tobinai, Michinori Ogura, Yukio Kobayashi, Toshiki Uchida, Takashi Watanabe, Takashi Oyama, Dai Maruyama, Tatsuya Suzuki, Masakazu Mori, Masanobu Kasai, Damien M. Cronier, James E. Wooldridge, Minori Koshiji	25
11	Multicenter phase II study of bendamustine for relapsed or refractory indolent B‐cell non‐Hodgkin lymphoma and mantle cell lymphoma 2010 ·Cancer Science ·Ken Ohmachi, Kiyoshi Ando, Michinori Ogura, Toshiki Uchida, Kuniaki Itoh, Nobuko Kubota, Kenichi Ishizawa, Joji Yamamoto, Takashi Watanabe, Naokuni Uike, Ilseung Choi, Yasuhito Terui, Kensuke Usuki, Hirokazu Nagai, Nobuhiko Uoshima, Kensei Tobinai, (unknown)	50
12	Phase I study of inotuzumab ozogamicin (CMC‐544) in Japanese patients with follicular lymphoma pretreated with rituximab‐based therapy 2010 ·Cancer Science ·Michinori Ogura, Kensei Tobinai, Kiyohiko Hatake, Toshiki Uchida, Masanobu Kasai, Takashi Oyama, Tatsuya Suzuki, Yukio Kobayashi, Takashi Watanabe, Teruhisa Azuma, Masakazu Mori, Yasuhito Terui, Masahiro Yokoyama, Yuko Mishima, Shunji Takahashi, Chiho Ono, Junko Ohata	46
13	Phase I study of the oral mammalian target of rapamycin inhibitor everolimus (RAD001) in Japanese patients with relapsed or refractory non-Hodgkin lymphoma 2010 ·International Journal of Hematology ·Kensei Tobinai, Michinori Ogura, Dai Maruyama, Toshiki Uchida, Naokuni Uike, Ilseung Choi, Kenichi Ishizawa, Kuniaki Itoh, Kiyoshi Ando, Masafumi Taniwaki, N Shimada, Yukio Kobayashi	24
14	Phase II study of oral fludarabine in combination with rituximab for relapsed indolent B‐cell non‐Hodgkin lymphoma 2009 ·Cancer Science ·Kensei Tobinai, (unknown), Michinori Ogura, Kuniaki Itoh, Yasuo Morishima, Kiyoshi Ando, Masafumi Taniwaki, Takashi Watanabe, Joji Yamamoto, Toshiki Uchida, Masanobu Nakata, Takashi Terauchi, Shigeru Nawano, Masaki Matsusako, (unknown), Tomomitsu Hotta	7
15	Clinical characteristics of chronic graft-versus-host disease following umbilical cord blood transplantation for adults 2008 ·Bone Marrow Transplantation ·Kyoko Sugimoto, Hiroto Narimatsu, Takakazu Kawase, Hiroatsu Iida, Mizuki Watanabe, A Kohno, Yachiyo Kuwatsuka, Toshiki Uchida, Motohiro Hamaguchi, Seitaro Terakura, T Naoe, Keitaro Matsuo, Makoto Murata, (unknown), Koichi Miyamura, Y Morishita, (unknown)	4
16	Enhanced cytotoxic effect of Ara-C by low intensity ultrasound to HL-60 cells 2000 ·Cancer Letters ·Katsuro Tachibana, Toshiki Uchida, Kazuo Tamura, Haruhiko Eguchi, Nobuya Yamashita, K. Ogawa	81
17	Clonality analysis by methylation-specific PCR for the human androgen-receptor gene (HUMARA-MSP) 2000 ·Leukemia ·Toshiki Uchida, Haruhiko Ohashi, Etsuko Aoki, (unknown), T Hotta, Takashi Murate, Hidehiko Saito, T. Kinoshita	31
18	hSNF5/INI1 gene mutations in lymphoid malignancy 2000 ·Cancer Genetics and Cytogenetics ·(unknown), Hirokazu Nagai, Toshiki Uchida, Takashi Murate, Yasuhide Hayashi, Tomomitsu Hotta, Hidehiko Saito, Tomohiro Kinoshita	26
19	Elimination of adult T cell leukemia cells by ultrasound in the presence of porfimer sodium 1997 ·Anti-Cancer Drugs ·Toshiki Uchida, Katsuro Tachibana, (unknown), (unknown)	21
20	[Fourth Early Breast Cancer Trialists' Collaborative Group meeting in Oxford--meta-analysis of early breast cancer clinical trials]. 1996 ·PubMed ·Junichi Sakamoto, (unknown), Toshiki Uchida, Mitsunori Yasue, Hiroaki Nakazato	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact